medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 4

<< Back Next >>

Med Int Mex 2022; 38 (4)

Effect of communication with mobile devices in hospitalized patients due to COVID-19

Fernández-Ortega MÁ, Nájera-Chávez P, Ponce-Rosas ER, Dávila-Mendoza R, Muñiz-Salinas DA, Rodríguez-Mendoza O, Sánchez-Pozos V, Pliego-Reyes CL

Language: Spanish
References: 22
Page: 804-810
PDF size: 204.06 Kb.


ABSTRACT

Objective: To identify the effect of mobile communication devices on the clinical evolution of hospitalized patients with SARS-CoV-2 pneumonia.
Materials and Methods: Controlled clinical trial, done from December 2020 to May 2021 in which patients with a diagnosis of SARS-CoV-2 pneumonia, both sexes, older than 18 years, with O2 saturation greater than 70% and lesser than 90% at admission were included. Two groups were formed, the independent variable was the availability of a mobile device: Group 1: patients with communication with relatives through video calls and Group 2: patients without communication with relatives. Dependent variables were days of in-hospital stay, hospitalization costs, comorbidities, complications, outcome: death or discharge, anxiety and depression.
Results: The most frequent complications were: metabolic disorder, endotracheal intubation and multiple organ failure, there were no significant differences between groups. The average length of in-hospital stay was 12.64 days, there were no differences between the two groups and no differences were found in the outcome. The cost per patient (bed days, medications, paraclinical studies and imaging studies) was 110,848.59 Mexican pesos (5542 American dollars).
Conclusions: The use of mobile communication devices in the areas did not improve the clinical evolution of hospitalized patients diagnosed with COVID-19 pneumonia. Nor did it reduce costs of care or days of hospital stay.


REFERENCES

  1. Johns Hopkins University Medicine (28/sept/2021). MortalityAnalyses. Disponible en: https://coronavirus.jhu.edu/data/mortality.

  2. Report of the WHO-China Joint Mission on CoronavirusDisease 2019 (COVID-19. 16-24 February 2020. [Consultado22 junio 2020]. Disponible en: https://www.who.int/publications/i/item/report-of-the-who-china-jointmission-on-coronavirus-disease-2019-(covid-19).

  3. Ministerio de Sanidad. Información científica- técnica.Enfermedad por coronavirus Covid-19 (actualización 03de julio de 2020). [Consultado 20/06/2020] Disponibleen: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/ITCoronavirus.pdf.

  4. Centros para el Control y la Prevención de Enfermedades(CDC). Enfermedad del coronavirus 2019 (COVID-19).Síntomas de la enfermedad del coronavirus. [Consultado21 junio 2020]. Disponible en: https://espanol.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.

  5. Centro de Coordinación de Alertas y Emergencias Sanitarias.Dirección General de sanidad y Consumo. DirecciónGeneral de Salud Pública, Calidad e Innovación. Ministeriode Sanidad. Enfermedad por coronavirus, COVID-19. Actualización,2 de junio 2020. [Consultado 21 junio 2020].Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/ITCoronavirus.pdf.

  6. Centros para el Control y la Prevención de Enfermedades(CDC). Enfermedad del coronavirus 2019. Personas conmayor riesgo. [consultado 21 junio 2020]. Disponible en:https://espanol.cdc.gov/coronavirus/2019-ncov/needextra-precautions/people-at-higher-risk.html.

  7. Ministerio de Sanidad. Información científica- técnica.Enfermedad por coronavirus SARS-CoV-2 (actualización15 de enero de 2021). [Consultado 12/08/2021] Disponibleen:https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/ITCoronavirus.pdf.

  8. Banerjee D, Rai M. Social isolation in Covid-19: The impactof loneliness [published online ahead of print, 2020Apr 29]. Int J Soc Psychiatry 2020; 20764020922269.doi:10.1177/0020764020922269.

  9. Hwang TJ, Rabheru K, Peisah C, Reichman W, Ikeda M.Loneliness and social isolation during the COVID-19pandemic. Int Psychogeriatr 2020; 1-4. doi:10.1017/S1041610220000988.

  10. Holt-Lunstad J, Smith TB, Layton JB. Social relationships andmortality risk: a meta-analytic review. PLoS Med 2010; 7(7): e1000316. doi:10.1371/journal.pmed.1000316.

  11. Jansen L, van Schijndel M, van Waarde J, van BusschbachJ. Health-economic outcomes in hospital patients withmedical-psychiatric comorbidity: A systematic review andmeta-analysis. PLoS One 2018; 13 (3): e0194029. https://doi.org/10.1371/journal.pone.0194029.

  12. Dubey S, Biswas P, Ghosh R , Chatterjee S, Dubey MJ,Chatterjee S, et al. Psychosocial impact of COVID-19. DiabetesMetab Syndr 2020; 14 (5): 779-788. doi:10.1016/j.dsx.2020.05.035.

  13. Steptoe A, Shankar A, Demakakos P, Wardle J. Social isolation,loneliness, and all-cause mortality in older men andwomen. Proc Natl Acad Sci USA 2013; 110 (15): 5797-5801.doi:10.1073/pnas.1219686110.

  14. Tsai HH, Tsai YF. Changes in depressive symptoms, socialsupport, and loneliness over 1 year after a minimum3-month videoconference program for older nursinghome residents. J Med Internet Res 2011; 13 (4): e93.doi:10.2196/jmir.1678.

  15. Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW, Wang Ch.Independent effect of depression and anxiety on chronicobstructive pulmonary disease exacerbations and hospitalizations.Am J Respir Crit Care Med 2008; 178: 913-920.doi: 10.1164/rccm.200804-619OC.

  16. Bessière K, Pressman S, Kiesler S, Kraut R. Effects of internetuse on health and depression: a longitudinal study. JMed Internet Res 2010; 12 (1): e6. doi: 10.2196/jmir.1149.

  17. Tsai HH, Tsai YF, Wang HH, Chang YC, Chu HH. Videoconferenceprogram enhances social support, loneliness, anddepressive symptoms of elderly nursing home residents.Aging Ment Health 2010; 14 (8): 947-954. doi:10.1080/13607863.2010.501057.

  18. Bartsch, S, Ferguson M, Mckinnell J & O'Shea K, Wedlock P,Sheryl S, Lee B. The potential health care costs and resourceuse associated With COVID-19 in The United States: Asimulation estimate of the direct medical costs and healthcare resource use associated with COVID-19 infections inthe United States. Health Affairs 2020; 39 (6): 1-7. DOI:10.1377/hlthaff.2020.00426.

  19. Jeck J, Jakobs F, Kron A, Franz J, Cornely OA, Kron F. A costof illness study of COVID-19 patients and retrospectivemodelling of potential cost savings when administeringremdesivir during the pandemic “first wave” in a Germantertiary care hospital. Infection 2022; 50: 191-201. doi:10.1007/s15010-021-01685-8.

  20. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L,Chernyak Y, et al. Factors associated with hospital admissionand critical illness among 5279 people with coronavirusdisease 2019 in New York City: prospective cohortstudy. BMJ 2020; 369:m1966. doi: 10.1136/bmj.m1966.

  21. Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q,et al. Clinical characteristics of 140 patients infected withSARS-CoV-2 in Wuhan, China. Allergy 2020; 75 (7): 1730-41.doi: 10.1111/all.14238.

  22. Cleary SM, Wilkinson T, Tamandjou TR, Docrat S, SolankiGC. Cost‐effectiveness of intensive care for hospitalizedCOVID-19 patients: experience from South Africa. HealthServices Research 2021; 21: 82. https://doi.org/10.1186/s12913-021-06081-4.




2020     |     www.medigraphic.com